Monoclonal antibodies provide small benefits in Alzheimer’s disease
Jan 26, 2024
Harms include increased risks for amyloid-related imaging abnormalities (ARIA)-edema, ARIA-hemorrhage and symptomatic ARIA-edema.
Ultrasound tech could allow for ultrafast Alzheimer’s treatment, study finds
By
Aaron Dorman
Jan 09, 2024
Researchers have found a way to deliver Alzheimer’s drugs faster via focused ultrasound technology, a new study shows.
Legislation aims to ensure ‘fair and accurate’ Alzheimer’s treatment coverage decisions
By
Kimberly Bonvissuto
Nov 21, 2023
Federal legislation that would prevent the federal government from imposing wide-reaching coverage restrictions on Alzheimer’s treatments was reintroduced last week, providing “fair and accurate”...
Eligibility limited for anti-β amyloid mAbs in seniors with MCI
Aug 18, 2023
Few older adults with mild cognitive impairment or mild dementia were eligible for lecanemab or aducanumab after applying clinical trial criteria.
Lawmakers turn up heat on CMS to expand access to Alzheimer’s treatments
By
Kimberly Bonvissuto
Apr 28, 2023
Medicare needs to reconsider its national coverage decision on FDA-approved Alzheimer’s drug treatments, bipartisan members of the House told Centers for Medicare & Medicaid Services Administrator Chiquita...
Focus on briefs: Dementia
Feb 01, 2023
Alzheimer’s blood test, Aducanumab approval issues, Medicare coverage of brain scans that diagnose dementia, Some at higher risk for Alzheimer’s
FDA approves second drug for Alzheimer’s disease, despite safety concerns
Jan 06, 2023
The approval of lecanemab-irmb (Leqembi) comes after controversial approval in 2021 of aducanumab (Aduhelm), which met with criticism over concerns about that drug’s effectiveness, safety and pricing.
Alzheimer’s Association asks CMS to provide full coverage of FDA-approved dementia drugs
By
Kimberly Bonvissuto
Dec 21, 2022
Every day, more than 2,000 older adults living with mild dementia may transition to a more advanced stage of the disease and no longer be eligible for lecanemab and other antibodies targeting amyloid under...
Alzheimer’s experts throw support behind experimental drug despite adverse events, deaths
By
Kimberly Bonvissuto
Dec 01, 2022
Alzheimer’s disease experts are throwing their support behind the drug lecanemab, despite reports of two deaths tied to the experimental monoclonal antibody medication.
A stumbling block on the way to an Alzheimer’s cure
By
Lois A. Bowers
Nov 14, 2022
In a new study, 56% of participants said they were not likely to take part in a trial of a dementia-prevention drug. Senior living may be able to play a role in decreasing that percentage.